- Previous Close
7.90 - Open
8.26 - Bid 8.06 x --
- Ask 8.28 x --
- Day's Range
8.10 - 8.90 - 52 Week Range
5.98 - 16.80 - Volume
23,132 - Avg. Volume
27,709 - Market Cap (intraday)
202.784M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.44 - Earnings Date Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.00
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
www.corline.seRecent News: CLBIO.ST
View MorePerformance Overview: CLBIO.ST
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLBIO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLBIO.ST
View MoreValuation Measures
Market Cap
202.78M
Enterprise Value
195.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.81
Price/Book (mrq)
2.40
Enterprise Value/Revenue
13.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.02%
Return on Assets (ttm)
-6.25%
Return on Equity (ttm)
-10.80%
Revenue (ttm)
23.48M
Net Income Avi to Common (ttm)
-9.63M
Diluted EPS (ttm)
-0.44
Balance Sheet and Cash Flow
Total Cash (mrq)
7.33M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.28M